A- A A+

OUD Care Service Improvement with Prolonged-release Buprenorphine in Prisons: Cost Estimation Analysis. 

Wright N, Hard J, Fearns C, Gilman M, Littlewood R, Clegg R, Parimelalagan L, Alam F. 

Clinicoecon Outcomes Res. 2020;12:499-504, doi.org/10.2147/CEOR.S256714

https://www.dovepress.com/oud-care-service-improvement-with-prolonged-release-buprenorphine-in-p-peer-reviewed-fulltext-article-CEOR

Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder. 

Tompkins CNE, Neale J, Strang J. J Subst Abuse Treat. 2019;104:64-71. doi:10.1016/j.jsat.2019.06.007

https://www.journalofsubstanceabusetreatment.com/article/S0740-5472(19)30102-3/fulltext

Buprenorphine Treatment for Opioid Use Disorder: An Overview. 

Shulman M, Wai JM, Nunes EV. 

CNS Drugs. 2019;33(6):567-580. doi:10.1007/s40263-019-00637-z

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585403/

Buprenorphine Treatment for Opioid Use Disorder in Community‐Based Settings: Outcome Related to Intensity of Services and Urine Drug Test Results. 

Galanter, M., Femino, J., Hunter, B. and Hauser, M. (2020), 

Am J Addict, 29: 271-278. doi:10.1111/ajad.13001

https://onlinelibrary.wiley.com/doi/full/10.1111/ajad.13001

Subcutaneous Extended-Release Buprenorphine Use in Pregnancy. 

Towers CV, Deisher H. 

Case Rep Obstet Gynecol. 2020;2020:3127676. Published 2020 Jul 17. doi:10.1155/2020/3127676

Subcutaneous Extended-Release Buprenorphine Use in Pregnancy. 

Vorteile und Chancen von Depot-Buprenorphin in der alltäglichen Praxis

Mannheim/Lund, 29.07.2020 – Mit der wachsenden Erfahrung zum Einsatz des Depot-Buprenorphin Buvidal® seit seiner Einführung im Februar 2019 zeichnen sich die Vorteile und Chancen dieser Behandlungsform deutlicher ab. Auch durch die Coronakrise haben sich die Vergabegewohnheiten verändert. Darüber tau schten sich erfahrene Suchtmediziner*innen jüngst im Rahmen eines von der Camurus GmbH unterstützten Webinars aus. (Camurus, 29.07.2020)

Camurus Webinarbericht_final_28072020Vorteile und Chancen von Depot-Buprenorphin in der alltäglichen Praxis

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study

Larance B, Byrne M, Lintzeris N On behalf of the CoLAB study team, et al

BMJ Open 2020;10:e034389. doi: 10.1136/bmjopen-2019-034389 

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study

Buprenorphine. Alan Cowan, researcher who helped develop drug used to treat opioid addiction, dies at 77

Alan Cowan, 77, of Ambler, a Philadelphia pharmacology professor, and before that a researcher who in his first professional job helped develop a drug that was used to treat opioid addiction, died Tuesday, June 30, at his home.

(…)

From 1971 to 1976, while employed by Reckitt & Colman Ltd. in Britain, he was part of a small research team that developed the drug buprenorphine. (The Philadelphia Inquirer, USA, 07.07.2020)

https://www.inquirer.com/obituaries/alan-cowan-phd-school-of-medicine-temple-university-philadelphia-drug-research-suboxone-addiction-opioid-dies-died-obituary-20200707.html

Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates. 

Kovar L, Schräpel C, Selzer D, et al. 

Pharmaceutics. 2020;12(6):E578. Published 2020 Jun 23. doi:10.3390/pharmaceutics12060578

https://www.mdpi.com/1999-4923/12/6/578

An Efficient and Smooth Methadone-to-Buprenorphine Transition Protocol Utilizing a Transdermal Fentanyl Bridge and a Pharmacokinetic Inducer: The Stanciu Method. 

Stanciu CN, Gibson S, Teja N, Healey CJ. 

Cureus. 2020;12(5):e8310. Published 2020 May 27.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320635/

Barriers to Prescribing Buprenorphine in the Emergency Department. 

Kim HS, Samuels EA. Overcoming 

JAMA Netw Open. 2020;3(5):e204996. doi:10.1001/jamanetworkopen.2020.4996

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765700

USA. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Full Document.

This updated Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. (SAMHSA - Substance Abuse & Mental Health Services Administration, USA, Mai 2020)

https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP20-02-01-006.pdf

CLINICAL GUIDELINES FOR USE OF DEPOT BUPRENORPHINE (BUVIDAL®) IN THE TREATMENT OF OPIOID DEPENDENCE

This Clinical Guideline has been developed to inform decision-making by clinicians prescribing and/or patients being treated with Buvidal® long-acting injected buprenorphine preparations.

This guideline was funded by Camurus Ltd. The funding enabled SMMGP to provide clinical, managerial, editorial and administrative input. (SMMGP - Substance Misuse Management in General Practice, UK, April 2020)

https://www.smmgp-fdap.org.uk/clinical-guidelines-for-use-of-depot-buprenorphine-buvidal-in-the-treatment-of-opioid-dependence

EMA. Summary of opinion (post authorisation): Suboxone (buprenorphine / naloxone) sublingual film

On 30 April 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Suboxone. The marketing authorisation holder for this medicinal product is Indivior Europe Limited. 

The CHMP adopted a new pharmaceutical form (sublingual film) associated with four new strengths (2/0.5, 4/1, 8/2, and 16/4 mg) for either sublingual or buccal use. The new formulation adds additional safety features to prevent intravenous misuse. (EMA - European Medicines Agency, Amsterdam, 30 April 2020, EMA/CHMP/219873/2020, Committee for Medicinal Products for Human Use (CHMP) 

https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-suboxone-x-42_en.pdf

Two world first studies of depot buprenorphine completed

Two world first studies of depot buprenorphine have recently been completed. Both studies are great achievements at the forefront of international research efforts in this field and have salience as part of the response to COVID-19. (NDARC - National Drug and Alcohol Research Centre, Australien, April 2020)

https://ndarc.med.unsw.edu.au/two-world-first-studies-depot-buprenorphine-completed

Progress Report on EMBED: A Pragmatic Trial of User-Centered Clinical Decision Support to Implement EMergency Department-Initiated BuprenorphinE for Opioid Use Disorder.

Melnick ER, Nath B, Ahmed OM, Brandt C, Chartash D, Dziura JD, Hess EP, Holland WC, Hoppe JA, Jeffery MM, Katsovich L, Li F, Lu CC, Maciejewski K, Maleska M, Mao JA, Martel S, Michael S, Paek H, Patel MD, Platts-Mills TF, Rajeevan H, Ray JM, Skains RM, Soares WE 3rd, Deutsch A, Solad Y, D'Onofrio G.

J Psychiatr Brain Sci. 2020;5. pii: e200003. doi: 10.20900/jpbs.20200003. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164817/

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis.

Andorn AC, Haight BR, Shinde S, Fudala PJ, Zhao Y, Heidbreder C, Learned SM, Fox NL, Nadipelli VR, Hassman D, Rutrick D.

J Clin Psychopharmacol. 2020 Apr 9. doi: 10.1097/JCP.0000000000001195.

Download -> PDF -> open access

https://journals.lww.com/psychopharmacology/Abstract/9000/Treating_Opioid_Use_Disorder_With_a_Monthly.98443.aspx

Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state.

Bogan C, Jennings L, Haynes L, Barth K, Moreland A, Oros M, Goldsby S, Lane S, Funcell C, Brady K.

J Subst Abuse Treat. 2020 Mar;112S:73-78. doi: 10.1016/j.jsat.2020.02.007.

https://linkinghub.elsevier.com/retrieve/pii/S0740-5472(19)30592-6

Injectable buprenorphine for opioid use disorder: Effects on 1-year recovery outcomes

An extended release version of buprenorphine was recently approved by the FDA to treat opioid use disorder. Prior research has revealed the short-term benefits of buprenorphine on traditional treatment outcomes like substance use and acute harm (e.g., overdose). Building upon this literature, the current study assessed the longer-term effects of monthly buprenorphine injections on patient-centered outcomes like quality of life and health status, suggesting improved well-being up to 1 year of treatment. (Recovery Research Institute, USA, April 2020)

https://www.recoveryanswers.org/research-post/injectable-buprenorphine-1-year-outcomes/

Transitioning a patient from injectable opioid agonist therapy to sublingual buprenorphine/naloxone for the treatment of opioid use disorder using a microdosing approach.

Caulfield MDG, Brar R, Sutherland C, Nolan S.

BMJ Case Rep. 2020 Mar 25;13(3). pii: e233715. doi: 10.1136/bcr-2019-233715.

Abstract

https://casereports.bmj.com/content/13/3/e233715.long

Metabolic and Addiction Indices in Patients on Opioid Agonist Medication-Assisted Treatment: A Comparison of Buprenorphine and Methadone.

Elman I, Howard M, Borodovsky JT, Mysels D, Rott D, Borsook D, Albanese M.

Sci Rep. 2020 Mar 27;10(1):5617. doi: 10.1038/s41598-020-62556-0.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101411/

Emergency Department Clinicians' Attitudes Toward Opioid Use Disorder and Emergency Department-initiated Buprenorphine Treatment: A Mixed-Methods Study.

Im DD, Chary A, Condella AL, Vongsachang H, Carlson LC, Vogel L, Martin A, Kunzler N, Weiner SG, Samuels-Kalow M.

West J Emerg Med. 2020 Feb 21;21(2):261-271. doi: 10.5811/westjem.2019.11.44382.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081867/

Perioperative Management of a Patient Taking Suboxone® at the Time of Ambulatory Surgery.

Malan SH, Bailey CH, Khurmi N.

Case Rep Anesthesiol. 2020 Mar 9;2020:5628348. doi: 10.1155/2020/5628348. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085354/

Traditional Chinese Medicine-facilitated switch from methadone to buprenorphine-naloxone for treatment of heroin dependence: a case report.

Huang KY, Hsu CH, Yu KC, Yeh YH, Han KC, Wei HT.

J Tradit Chin Med. 2019 Apr;39(2):281-284.

PMID: 32186053

http://www.journaltcm.com/modules/Journal/contents/stories/192/18.pdf

Rapid Induction Therapy for Opioid-Use Disorder Using Buprenorphine Transdermal Patch: A Case Series.

Saal D, Lee F.

Perm J. 2020;24. doi: 10.7812/TPP/19.124. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089594/

Buprenorphin-Depot: Annäherung an das Äquivalenzprinzip in Haft - Besondere Eignung von Buvidal® zur Substitutionstherapie in der JVA 

Mannheim/Lund, 13.12.2019 – Die 4. Gefängnismedizintage am 5. und 6. Dezember 2019 in Frankfurt stießen auf reges Interesse bei Medizinern und Pflegekräften im Vollzug. Dem von der Camurus GmbH unterstützten Symposium „Das Depot – neue Wege in der Behandlung der Opioidabhängigkeit im Justizvollzug“ wohnten etwa 200 Besucher*innen bei. Mit der wachsenden Verfügbarkeit des Buprenorphin-Depots in Justizvollzugsanstalten kann eine deutliche Annäherung an das geforderte Äquivalenzprinzip erreicht werden, so ein Fazit der Referate und nachfolgenden Diskussion. (Camurus, Mannheim/Lund, 13.12.2019)

https://www.buvidal.de/wp-content/uploads/2020/02/202012_Bericht_Symposium_Naeher_am_Aequivalenzprinzip_mit-Buprenorphin-Depot.pdf

Rapid effect of a single-dose buprenorphine on reduction of opioid craving and suicidal ideation: A randomized, double blind, placebo-controlled study.

Ahmadi J, Sarani EM, Jahromi MS.

Ci Ji Yi Xue Za Zhi. 2019 Mar 14;32(1):58-64. doi: 10.4103/tcmj.tcmj_220_18. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015018/

Buprenorphine to reverse respiratory depression from methadone overdose in opioid-dependent patients: a prospective randomized trial.

Zamani N, Buckley NA, Hassanian-Moghaddam H.

Crit Care. 2020 Feb 7;24(1):44. doi: 10.1186/s13054-020-2740-y.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006192/

Sexual dysfunction in men on buprenorphine - naloxone-based substitution therapy.

Mattoo SK, Ghosh A, Subodh BN, Basu D, Satapathy A, Prasad S, Sharma MP.

Indian J Psychiatry. 2020 Jan-Feb;62(1):66-72. doi: 10.4103/psychiatry.IndianJPsychiatry_195_19. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964450/

Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management.

Osborne V, Davies M, Roy D, Tescione F, Shakir SAW.

BMJ Evid Based Med. 2020 Feb 24. pii: bmjebm-2019-111295. doi: 10.1136/bmjebm-2019-111295.

https://ebm.bmj.com/content/early/2020/02/24/bmjebm-2019-111295.long

  1. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
  2. Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.
  3. Abuses of FDA Regulatory Procedures - The Case of Suboxone.
  4. Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study.
  5. Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach.